| China | Türkei | Österreich | |
| Chemotherapie bei Brustkrebs | von $14,800 | von $1,200 | von $15,000 |
Bookimed erhebt keine zusätzlichen Gebühren für Leberkrebs Stadium 4-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Leberkrebs Stadium 4 einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Leberkrebs Stadium 4-Behandlungsreise nie allein.
Dr. Liuying leitet die Onkologieabteilung des Jinshazhou Hospital der Guangzhou University of Chinese Medicine. Klinische Schwerpunkte sind hepatozelluläres Karzinom, Cholangiokarzinom sowie Lungen- und kolorektale Karzinome. Dr. Liuying verfügt über besondere Expertise bei Melanom und Melanom-Lebermetastasen. Interventionelle Verfahren umfassen MWA (Mikrowellenablation), RFA (Radiofrequenzablation), Kryoablation und die Implantation radioaktiver Seeds zur nichtvaskulären, minimalinvasiven Tumorablation.
Forschung: Teilnahme an zwei Wissenschafts- und Technologieprojekten der Provinz Guangdong. Mitwirkung am Expertenkonsens 2014 zur thermischen Ablation primärer und metastatischer Lungentumoren. Publikation im Chinese Journal of Lung Cancer. Zusammenstellung der Fallreihen Ausgewählte Fälle der Mikrowellenablation bei Lungentumoren und Ausgewählte Fälle der Mikrowellenablation bei Lebertumoren.
Ämter: Mitglied des Ständigen Ausschusses des Jugendausschusses für intratumorale Brachytherapie der China Medical Education Association. Mitglied des Ständigen Ausschusses des Fachkomitees für minimalinvasive interventionelle Medizin der Guangdong Primary Medical Association.
Professor Shixin Liu, MD, PhD, ist Fachbereichsleiter des Onkologiezentrums. Zuvor war er Präsident des Krebskrankenhauses der Provinz Jilin und Direktor des Forschungsinstituts für Krebsprävention und -therapie. Er ist Professor der zweiten Ebene und Promotionsbetreuer. Er erhielt die Sonderzulage des Staatsrats, die 4. Auszeichnung 'National Famous Doctor (Outstanding Contribution)' sowie den Ehrentitel 'Vorbild ärztlicher Ethik'.
Er ist auf die umfassende Diagnostik und Behandlung bösartiger Tumoren spezialisiert, mit Schwerpunkt auf präziser Strahlentherapie thorakaler und abdomineller Tumoren. Er beherrscht IMRT, VMAT und SBRT bei Lungen-, Speiseröhren-, Brust- und Rektumkarzinomen.
Zu seinen Leitungsfunktionen zählen die stellvertretenden Vorsitzämter bei CMA Radiation Oncology, CACA Radiotherapy und CACA Particle Therapy. Er gehört dem Ständigen Ausschuss der CSCO an und ist stellvertretender Vorsitzender des CSCO-Expertenkomitees für Strahlenonkologie. Zudem ist er stellvertretender Vorsitzender der CPAM Radiation Oncology und Mitglied des Ständigen Ausschusses der CSMEA. Er ist Vorsitzender der Sektion Strahlenonkologie der Jilin Medical Association. Er gehört den Redaktionsbeiräten des Chinese Journal of Radiation Oncology und des Practical Journal of Cancer an.
Chinese guidelines for stage 4 liver cancer prioritize systemic therapy combinations. The standard involves immune checkpoint inhibitors paired with anti-angiogenic drugs. Protocols like Sintilimab plus Bevacizumab are preferred. Chinese-developed medications like Donafenib and hepatic arterial infusion chemotherapy (HAIC) are also primary frontline options.
Bookimed Expert Insight: Chinese oncology centers often apply local interventional techniques that differ from Western standards. Fuda Cancer Hospital in Guangzhou provides NanoKnife and cryosurgery for late-stage patients. These methods serve as powerful local controls when used alongside systemic therapies. Data shows clinics managing 30,000+ international patients often use these to shrink tumors quickly.
Patient Consensus: Patients note that Chinese hospitals provide aggressive care even for advanced stages. They appreciate that facilities like Fuda Hospital offer hotel-like rooms with highly attentive nursing support.
China's Reduce and Remove strategy is a multi-step protocol for late-stage liver cancer. It uses radiation and immunotherapy to downstage inoperable tumors to stage 1. Once lesions shrink, surgeons perform curative resection or transplantation. This approach enables surgery for previously terminal cases.
Bookimed Expert Insight: Clinical data from centers like Fuda Cancer Hospital shows that high-volume facilities often utilize advanced ablation. Dr. Liuying has compiled microwave ablation textbooks specifically for liver tumors. This expertise allows doctors to target residual lesions that radiation might miss. Choosing a facility with both interventional and surgical departments is vital for the Remove phase.
Patient Consensus: Patients note that turning an inoperable case into an operable one is the primary goal. They emphasize that while shrinkage is hopeful, liver function and cirrhosis levels determine if surgery is ultimately safe.
Chinese hospitals utilize Hepatic Artery Infusion Chemotherapy (HAIC) because it delivers drug concentrations 300 to 400 times higher than systemic chemotherapy. This approach targets tumors directly via the hepatic artery. It specifically addresses advanced, Hepatitis B-driven cases common in Chinese patient populations.
Bookimed Expert Insight: While Western protocols often move to systemic therapy for stage 4 cases, Chinese centers like Fuda Cancer Hospital leverage high-volume interventional expertise. Their JCI-accredited facilities often combine HAIC with technologies like cryosurgery or NanoKnife. This aggressive multimodal strategy is why they successfully treat over 30,000 international patients with advanced stages.
Patient Consensus: Patients note that Chinese teams are much more aggressive about treating the liver directly. They often highlight that HAIC feels like a five-star hospital experience despite the intensive catheter-based nature of the treatment.
International patients can legally access approved Chinese cancer drugs through accredited medical centers. Enrollment in clinical trials is possible but complex. Access is typically managed through international departments at JCI-accredited facilities like Fuda Cancer Hospital. Success depends on genomic compatibility and strict regulatory compliance.
Bookimed Expert Insight: China's oncology landscape is unique because hospitals often specialize in specific ablation techniques. Fuda Cancer Hospital has treated over 30,000 international patients across 100 countries. Our data shows this high volume is due to their expertise in combining cryosurgery with NanoKnife. This specific combination is often absent in standard global protocols for stage 4 liver cancer.
Patient Consensus: Patients note that major hospitals provide high-quality rooms that feel like hotels. They emphasize the importance of having professional translation to ensure home-country doctors understand the Chinese diagnosis.
NanoKnife and cryosurgery are effective local therapies for stage 4 liver cancer in China. These technologies manage specific tumors within a systemic treatment plan. They help debulk larger masses and relieve symptoms. Surgeons use them when conventional surgery is not feasible.
Bookimed Expert Insight: Chinese oncology centers like Fuda Cancer Hospital offer over 10 types of minimally invasive therapies. This variety allows doctors to bypass traditional chemotherapy for some advanced cases. Dr. Liuying at Jinshazhou Hospital specifically trains other specialists in these ablation standards. This high concentration of expertise makes China a primary destination for complex, multi-modality tumor management.
Patient Consensus: Patients note that these procedures require specialized hospital stays despite being minimally invasive. They emphasize verifying the clinical team's specific experience with local ablation for liver-dominant disease.
Traditional Chinese Medicine (TCM) serves as a palliative support tool for Stage 4 liver cancer. It focuses on reducing symptoms like pain or nausea. Oncology centers in China typically use it alongside immunotherapy or ablation. This integrated approach aims to improve sleep and appetite during advanced care.
Bookimed Expert Insight: Data from JCI-accredited facilities like Fuda Cancer Hospital shows that successful Stage 4 care prioritizes technology over herbs. Clinicians often lead with NanoKnife or cryosurgery to control tumors before adding TCM. This sequence ensures that late-stage patients receive effective debulking before focusing solely on herbal symptom management.
Patient Consensus: Patients note that TCM-style care often makes the hospital experience feel more emotionally reassuring and familiar. While some find acupuncture helpful for relaxation, they emphasize that herbal supplements must be disclosed to avoid stressing the liver further.